Literature DB >> 28215653

Dendritic cells infected by Ad-sh-SOCS1 enhance cytokine-induced killer (CIK) cell immunotherapeutic efficacy in cervical cancer models.

Yi Zheng1, Bicheng Hu2, Shenggao Xie3, Xiaofan Chen3, Yuqian Hu3, Wanping Chen4, Shanshan Li5, Bo Hu6.   

Abstract

BACKGROUND AIMS: Cervical cancer constitutes a major problem in women's health worldwide, but the efficacy of the standard therapy is unsatisfactory. Cytokine-induced killer (CIK) cells exhibit antitumor activity against a variety of malignancies in preclinical models and have proven safe and effective in clinical trials. However, current CIK therapy has limitations and needs to be improved to meet the clinical requirements. The aim of this study was to investigate whether suppressing the expression of cytokine signaling 1 (SOCS1) in dendritic cells (DCs) can shorten in vitro CIK culture time and improve its antitumor efficacy.
METHODS: DCs were pre-cultured for 3 days before infected with adenovirus-mediated-SOCS1 short hairpin RNA (Ad-sh-SOCS1) and pulsed with CTL epitope peptides E7. The DCs infected by Ad-sh-SOCS1 (gmDCs) and CIKs were then co-cultured for 5 or 9 days, and CIK proliferation and antitumor activity were evaluated both in vitro and in vivo.
RESULTS: Our data show that gmDCs significantly stimulated the expansion of co-cultured CIKs and increased the secretion of interferon-γ and interleukin-12. Moreover, gmDCs-activated CIKs showed higher cytotoxic activity against TC-1 cells expressing HPV16E6 and E7. Our in vivo study showed that the mice infused with gmDCs-activated CIKs on day 10 had an increased survival rate and prolonged survival time compared with the controls.
CONCLUSIONS: Taken together, these results indicate that DCs modified by adenovirus-mediated SOCS1 silencing can promote CIKs expansion and enhance the efficacy of antitumor immunotherapy both in vitro and in vivo, which represents an effective therapeutic approach for cervical cancer and other tumors.
Copyright © 2017 International Society for Cellular Therapy. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  cervical cancer; cytokine-induced killer cells; dendritic cells; human papillomavirus; suppressors of cytokine signaling 1

Mesh:

Substances:

Year:  2017        PMID: 28215653     DOI: 10.1016/j.jcyt.2017.01.008

Source DB:  PubMed          Journal:  Cytotherapy        ISSN: 1465-3249            Impact factor:   5.414


  5 in total

1.  Combined Treatment with Autologous CIK Cells, Radiotherapy and Chemotherapy in Advanced Cervical Cancer.

Authors:  Ning Li; Yong-Wei Tian; Yue Xu; Dan-Dan Meng; Ling Gao; Wen-Jie Shen; Zong-Lan Liu; Zhi-Qiao Xu
Journal:  Pathol Oncol Res       Date:  2018-12-03       Impact factor: 3.201

2.  LAP+CD4+T cells regulate the anti-tumor role of CIK cells in colorectal cancer through IL-10 and TGF-β.

Authors:  Wu Zhong; Chuanfa Fang; Hongquan Liu; Lei Zhang; Xiaofei Zhang; Junqiao Zhong; Xianping He; Leichang Zhang
Journal:  Am J Transl Res       Date:  2022-06-15       Impact factor: 3.940

Review 3.  Targeted Gene Delivery Therapies for Cervical Cancer.

Authors:  Ángela Áyen; Yaiza Jiménez Martínez; Houria Boulaiz
Journal:  Cancers (Basel)       Date:  2020-05-21       Impact factor: 6.639

4.  The Antitumor Activity of CAR-T-PD1 Cells Enhanced by HPV16mE7-Pulsed and SOCS1-Silenced DCs in Cervical Cancer Models.

Authors:  Jingwei Zheng; Jingsong Huang; Wei Ma; Wenqiang Yang; Bicheng Hu
Journal:  Cancer Manag Res       Date:  2021-08-04       Impact factor: 3.989

5.  The Immunotherapeutic Effect of SIRPα-Silenced DCs against Cervical Cancer.

Authors:  Xiaojie Li; Wenying Zhou; Yanlan Liang; Changzhi Xu; Zhizhi Xie; Jiayin Liang; Bo Hu
Journal:  J Immunol Res       Date:  2020-01-07       Impact factor: 4.818

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.